<DOC>
	<DOCNO>NCT00507065</DOCNO>
	<brief_summary>Assess safety efficacy ADDERALL XR compare placebo treatment adolescent ( age 13-17 ) ADHD . Subjects assign one two cohort base weight ( &lt; = 75 kg &gt; 75 kg ) .</brief_summary>
	<brief_title>Safety Efficacy ADDERALL XR Treatment Adolescents Aged 13-17 With Attention Deficit Hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Amphetamine</mesh_term>
	<mesh_term>Adderall</mesh_term>
	<criteria>Males/females 1317 year age meeting DSMIV criterion primary diagnosis ADHD Controlled uncontrolled comorbid psychiatric diagnosis ( except ODD ) significant symptom PTSD , psychosis , bipolar disease , severe OCD Known nonresponder stimulant medication Documented allergy intolerance ADDERALL , ADDERALL XR amphetamine Conduct Disorder , hypertension , history seizure Tic disorder Tourette 's disorder</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>